Pub Date : 2024-07-05DOI: 10.25073/2588-1132/vnumps.4664
Nguyen Duc Anh, Hoang Thanh Tung, Le Thi Hong Nhung
Introduction: Leber hereditary optic neuropathy (LHON) is a rare genetic condition characterized by bilateral irreversible vision loss, predominantly affecting young males. Case presentation: We report two clinical cases of two young male patients who were admitted to the hospital because of painless vision loss. Their family members either have the LHON condition or carry a mutation of that in their gene. Fundoscopic examination of the optic nerve currently appeared to have temporal pallor. Orbital Magnetic Resonance Imaging (MRI) scan showed hyperintensity of the optic nerve. Optical Coherence Tomography (OCT) of the optic nerve head and retinal nerve fiber layer showed thinning of the temporal nerve fiber layer. Humphrey visual field revealed paracentral scotoma. Genetic testing revealed the patients had a m.11778G > A mutation in MT-ND4 gene. They were both treated with oral Coenzyme Q10 and Idebenone. Conclusions: Leber's hereditary optic neuropathy may mimic optic neuritis in the acute phase, requiring precise, systematic clinical evaluation and genetic testing for confirmation.
{"title":"Leber Hereditary Optic Neuropathy: Report of Two Cases and Clinical Overview","authors":"Nguyen Duc Anh, Hoang Thanh Tung, Le Thi Hong Nhung","doi":"10.25073/2588-1132/vnumps.4664","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4664","url":null,"abstract":"Introduction: Leber hereditary optic neuropathy (LHON) is a rare genetic condition characterized by bilateral irreversible vision loss, predominantly affecting young males. Case presentation: We report two clinical cases of two young male patients who were admitted to the hospital because of painless vision loss. Their family members either have the LHON condition or carry a mutation of that in their gene. Fundoscopic examination of the optic nerve currently appeared to have temporal pallor. Orbital Magnetic Resonance Imaging (MRI) scan showed hyperintensity of the optic nerve. Optical Coherence Tomography (OCT) of the optic nerve head and retinal nerve fiber layer showed thinning of the temporal nerve fiber layer. Humphrey visual field revealed paracentral scotoma. Genetic testing revealed the patients had a m.11778G > A mutation in MT-ND4 gene. They were both treated with oral Coenzyme Q10 and Idebenone. Conclusions: Leber's hereditary optic neuropathy may mimic optic neuritis in the acute phase, requiring precise, systematic clinical evaluation and genetic testing for confirmation. \u0000 \u0000 \u0000 \u0000 ","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":" 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141676787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-16DOI: 10.25073/2588-1132/vnumps.4550
Vu Ngoc Anh, Vu Van Nga, Le Thi Minh Phuong, Do Thi Le Hang, Bui Son Nhat, Dinh Thi My Dung, Han Minh Thuy
The study aims to describe the situation of using antihypertensive and hypoglycemic drugs; Initial evaluation of the effectiveness of drug used in the treatment regimen of patients with concomitant hypertension and type 2 diabetes. Methods: a cross-sectional, retrospective study was performed on 179 medical records of patients who had hypertension and type 2 diabetes, examination and treatment at the Internal Medicine Department - Hospital E from April 2020 to December 2022. Information collected from medical records was processed using SPSS 26.0 statistical software. Result: the main groups of hypoglycemic drugs used were metformin (74.9%) and insulin (69,3%). The rate of using multi-drug regimen for diabetes (64.8%) is higher than that of monotherapy, in which the two-drug regimen of insulin and biguanide (metformin) is common (32.4%). The main groups of antihypertensive drugs used were ACE inhibitors and Ca channel blockers (72.6% and 57.5%), 60.3% of patients were treated according to a multi-drug regimen in which combination regimens of 2 groups of Ca channel blockers and ACE inhibitors are common (26.3%). There are no clinically significant interactions between antidiabetic and antihypertensive drugs. The rate of patients who reached the target blood pressure was 83.8%. The rate of patients achieving target blood sugar levels when discharged from the hospital was 40.9%. Conclusion: multi-drug regimen is used more than monotherapy in the treatment of hypertension and diabetes. Most patients reached target blood pressure on discharge, however the number of patients achieving target blood glucose was quite limited . No drug interactions were found between drugs used to lower blood pressure and hypoglycemic drugs.
{"title":"Survey on the Use of Medicines in Patients with Co-existing Hypertension and Type 2 Diabetes at the Internal Medicine Department of E Hospital in 2020-2022","authors":"Vu Ngoc Anh, Vu Van Nga, Le Thi Minh Phuong, Do Thi Le Hang, Bui Son Nhat, Dinh Thi My Dung, Han Minh Thuy","doi":"10.25073/2588-1132/vnumps.4550","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4550","url":null,"abstract":"The study aims to describe the situation of using antihypertensive and hypoglycemic drugs; Initial evaluation of the effectiveness of drug used in the treatment regimen of patients with concomitant hypertension and type 2 diabetes. Methods: a cross-sectional, retrospective study was performed on 179 medical records of patients who had hypertension and type 2 diabetes, examination and treatment at the Internal Medicine Department - Hospital E from April 2020 to December 2022. Information collected from medical records was processed using SPSS 26.0 statistical software. Result: the main groups of hypoglycemic drugs used were metformin (74.9%) and insulin (69,3%). The rate of using multi-drug regimen for diabetes (64.8%) is higher than that of monotherapy, in which the two-drug regimen of insulin and biguanide (metformin) is common (32.4%). The main groups of antihypertensive drugs used were ACE inhibitors and Ca channel blockers (72.6% and 57.5%), 60.3% of patients were treated according to a multi-drug regimen in which combination regimens of 2 groups of Ca channel blockers and ACE inhibitors are common (26.3%). There are no clinically significant interactions between antidiabetic and antihypertensive drugs. The rate of patients who reached the target blood pressure was 83.8%. The rate of patients achieving target blood sugar levels when discharged from the hospital was 40.9%. Conclusion: multi-drug regimen is used more than monotherapy in the treatment of hypertension and diabetes. Most patients reached target blood pressure on discharge, however the number of patients achieving target blood glucose was quite limited . No drug interactions were found between drugs used to lower blood pressure and hypoglycemic drugs. \u0000 ","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"26 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140696569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-16DOI: 10.25073/2588-1132/vnumps.4582
Phung Thao Nguyen, Ha Van Thuy, Bui Thi Xuan
Tisagenlecleucel is a new immunological therapy in refractory or relapsed B-cell lymphoblastic leukemia with high expense. Objective: To assess the quality as well as analyze characteristics and results of cost-effectiveness analysis (CEA) of tisagenlecleucel immunological therapy in children with R/R B-ALL. Method: To analyze systematic review of articles published during the period of 2017-2023 in Pubmed, ScienceDirect, GoogleScholar, Cochrane databases. Result: 10 selected studies were carried out in 8 nations with different cost units and discount rates. Compared therapies were standard therapy of each country included Blinatumomab, Clo-C, Clo-M, FLA-IDA, FLAG-IDA. Of 10 studies, 70% was considered cost-effectiveness, 20% non-conclusion and only 10% not cost-effectiveness. Conclusion: Tisagenlecleucel’s cost is the highest among compared therapies but it can be cost-effective in a nation with WTP threshold of $100.000-$150.000. Keywords: Systematic review, cost-effective, tisagenlecleucel, CAR-T, acute lymphoblastic leukemia.
{"title":"Tisagenlecleucel for Treatment of Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia (R/R B-All): A Systematic Review of Cost-Effectiveness Analysis","authors":"Phung Thao Nguyen, Ha Van Thuy, Bui Thi Xuan","doi":"10.25073/2588-1132/vnumps.4582","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4582","url":null,"abstract":"Tisagenlecleucel is a new immunological therapy in refractory or relapsed B-cell lymphoblastic leukemia with high expense. Objective: To assess the quality as well as analyze characteristics and results of cost-effectiveness analysis (CEA) of tisagenlecleucel immunological therapy in children with R/R B-ALL. Method: To analyze systematic review of articles published during the period of 2017-2023 in Pubmed, ScienceDirect, GoogleScholar, Cochrane databases. Result: 10 selected studies were carried out in 8 nations with different cost units and discount rates. Compared therapies were standard therapy of each country included Blinatumomab, Clo-C, Clo-M, FLA-IDA, FLAG-IDA. Of 10 studies, 70% was considered cost-effectiveness, 20% non-conclusion and only 10% not cost-effectiveness. Conclusion: Tisagenlecleucel’s cost is the highest among compared therapies but it can be cost-effective in a nation with WTP threshold of $100.000-$150.000. \u0000Keywords: Systematic review, cost-effective, tisagenlecleucel, CAR-T, acute lymphoblastic leukemia. \u0000 \u0000 ","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140697361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-03DOI: 10.25073/2588-1132/vnumps.4585
Do Thi Dinh, Nguyen Thi Van Anh, N. Van Khanh, Dao Viet Hung, Nguyen Thi Thanh Hai, Pham Quoc Tuan
The Kien ty syrup is formulated from six medicinal materials, including Pericarpium Citri Reticulatae, Fructus Aurantii immaturus, Radix Codonopsis, Rhizoma Atractylodis macrocephalae, Fructus Crataegi, Fructus Hordei germinatus and sodium benzoate as a preservative. Hesperidin, a bioflavonoid found in Pericarpium Citri Reticulatae, Fructus Aurantii immaturus, is used to assess the syrup's quality in terms of assay. In this study, an HPLC method for simultaneous determination of hesperidin and sodium benzoate in Kien ty syrup was developed. The method was performed on an Agilent C18 column (250 × 4.6 mm; 5 μm) with the mobile phase being a mixture of 0.05 M phosphate buffer solution pH 5.5: acetonitrile (70:30, v/v), running in a isocratic elution mode. The flow rate was set at 1.0 mL/min, and the injection volume was 10 μL. The analytes were detected at 225 nm. The method was validated and met the requirements according to ICH, AOAC guidelines. Applying the developed quantification method, the analysis of three sirup lots revealed that the content of hesperidin and sodium benzoate ranged from 0.480-0.504 mg/mL and 2.869-2.306 mg/mL, respectively. The study results indicate that this quantification method can be applied for simultaneous determination of hesperidin and sodium benzoate in Kien ty syrup and similar products.
{"title":"Development of an High Performance Liquid Chromatography Method for Simultaneous Determination of Hesperidin and Sodium Benzoate in Kien Ty Syrup","authors":"Do Thi Dinh, Nguyen Thi Van Anh, N. Van Khanh, Dao Viet Hung, Nguyen Thi Thanh Hai, Pham Quoc Tuan","doi":"10.25073/2588-1132/vnumps.4585","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4585","url":null,"abstract":"The Kien ty syrup is formulated from six medicinal materials, including Pericarpium Citri Reticulatae, Fructus Aurantii immaturus, Radix Codonopsis, Rhizoma Atractylodis macrocephalae, Fructus Crataegi, Fructus Hordei germinatus and sodium benzoate as a preservative. Hesperidin, a bioflavonoid found in Pericarpium Citri Reticulatae, Fructus Aurantii immaturus, is used to assess the syrup's quality in terms of assay. In this study, an HPLC method for simultaneous determination of hesperidin and sodium benzoate in Kien ty syrup was developed. The method was performed on an Agilent C18 column (250 × 4.6 mm; 5 μm) with the mobile phase being a mixture of 0.05 M phosphate buffer solution pH 5.5: acetonitrile (70:30, v/v), running in a isocratic elution mode. The flow rate was set at 1.0 mL/min, and the injection volume was 10 μL. The analytes were detected at 225 nm. The method was validated and met the requirements according to ICH, AOAC guidelines. Applying the developed quantification method, the analysis of three sirup lots revealed that the content of hesperidin and sodium benzoate ranged from 0.480-0.504 mg/mL and 2.869-2.306 mg/mL, respectively. The study results indicate that this quantification method can be applied for simultaneous determination of hesperidin and sodium benzoate in Kien ty syrup and similar products. \u0000 ","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140746988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-22DOI: 10.25073/2588-1132/vnumps.4562
N. Giang, Nguyen Trong Ha, Nguyen Thi Xuan
Non-Hodgkin's lymphoma (NHL) is a common hematological malignancy that develops in the lymphatic system. A20, CYLD, IFN-γ, JAK2, PI3KCA, and TP53 are known as inflammation-related genes in autoimmune diseases and cancers. In the end, 126 patients with NHL and 109 healthy individuals with well-characterized clinical profiles were enrolled. Twelve variants in the above genes were determined by the Kompetitive allele-specific PCR (KASP) assay. As a result, among genotyped 12 SNPs, the AG genotype of the rs280500 in the TYK2 gene showed significantly higher frequency in the patient group compared to healthy individuals (P=0.05). In addition, no significant differences in genotype frequencies of the other SNPs were found between the two groups. In conclusion, the rs280500 in the TYK2 gene was the risk variant for NHL susceptibility and additionally contributed to understanding the genetic basis of NHL.
{"title":"Association Analysis of Polymorphisms in Inflammation-Related Genes with Non-Hodgkin Lymphoma Susceptibility","authors":"N. Giang, Nguyen Trong Ha, Nguyen Thi Xuan","doi":"10.25073/2588-1132/vnumps.4562","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4562","url":null,"abstract":"Non-Hodgkin's lymphoma (NHL) is a common hematological malignancy that develops in the lymphatic system. A20, CYLD, IFN-γ, JAK2, PI3KCA, and TP53 are known as inflammation-related genes in autoimmune diseases and cancers. In the end, 126 patients with NHL and 109 healthy individuals with well-characterized clinical profiles were enrolled. Twelve variants in the above genes were determined by the Kompetitive allele-specific PCR (KASP) assay. As a result, among genotyped 12 SNPs, the AG genotype of the rs280500 in the TYK2 gene showed significantly higher frequency in the patient group compared to healthy individuals (P=0.05). In addition, no significant differences in genotype frequencies of the other SNPs were found between the two groups. In conclusion, the rs280500 in the TYK2 gene was the risk variant for NHL susceptibility and additionally contributed to understanding the genetic basis of NHL. \u0000 ","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":" 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140211589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-22DOI: 10.25073/2588-1132/vnumps.4571
Nguyen Thi Van Anh, Le Hong Luyen
Canna x generalis L.H Bailey & E.Z Bailey (CG) has been used as folk medicine to treat different diseases. However, scientific information about the pharmacological effects and chemical composition of this plant is still very limited. This study aims to evaluate for the first time the α-amylase and α-glucosidase inhibitory activity of CG rhizome extracts. The rhizome part of CG was extracted with ethanol and then fractionated with n-hexane, ethyl acetate, and water. The total extract and fractions were evaluated for their inhibitory effects on α-amylase and α-glucosidase enzymes in vitro. The results showed that the ethyl acetate fraction had the strongest inhibitory activity against α-amylase and α-glucosidase with IC50 values of 53.19 ± 2.79 and 95.83 ± 6.26 µg/mL, respectively. Therefore, the rhizome part of the CG plant, especially the ethyl acetate fraction, is a potential natural source for searching for active ingredients to prevent and treat diabetes.
{"title":"Evaluation of Anti--amylase and Anti--glucosidase Activity of Canna x Generalis L.H Bailey & E.Z Bailey Rhizome","authors":"Nguyen Thi Van Anh, Le Hong Luyen","doi":"10.25073/2588-1132/vnumps.4571","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4571","url":null,"abstract":"Canna x generalis L.H Bailey & E.Z Bailey (CG) has been used as folk medicine to treat different diseases. However, scientific information about the pharmacological effects and chemical composition of this plant is still very limited. This study aims to evaluate for the first time the α-amylase and α-glucosidase inhibitory activity of CG rhizome extracts. The rhizome part of CG was extracted with ethanol and then fractionated with n-hexane, ethyl acetate, and water. The total extract and fractions were evaluated for their inhibitory effects on α-amylase and α-glucosidase enzymes in vitro. The results showed that the ethyl acetate fraction had the strongest inhibitory activity against α-amylase and α-glucosidase with IC50 values of 53.19 ± 2.79 and 95.83 ± 6.26 µg/mL, respectively. Therefore, the rhizome part of the CG plant, especially the ethyl acetate fraction, is a potential natural source for searching for active ingredients to prevent and treat diabetes. \u0000 \u0000 \u0000 ","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":" 15","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140213047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-22DOI: 10.25073/2588-1132/vnumps.4578
Nguyen Thi Van Anh, Nguyen Ngoc Trang
Cardiovascular disease is one of the leading causes of death globally. The discovery and use of natural products in the prevention and treatment of cardiovascular diseases have achieved great interest. Oxalis debilis is traditionally used for the treatment of various ailments. This study aimed to investigate the potential antiplatelet and anticoagulant properties of extracts derived from O. debilis rhizome. The rhizome of O. debilis was extracted with methanol and then fractionated to obtain four extracts: the total methanol extract, the n-hexane, ethyl acetate, and water fraction. These four extracts were then tested for their ability to inhibit platelet aggregation and blood coagulation in human blood samples. This report demonstrated for the first time that O. debilis had inhibitory effects on platelet aggregation induced by both adenosine diphosphate and collagen as well as blood coagulation. Moreover, the total methanol extract, the ethyl acetate, and the water fraction had strong antiplatelet aggregation effects. All tested extracts had mild anticoagulant activities. This plant could be a valuable natural source for searching for antithrombotic substances, or for the development of supplementary products for the treatment and prevention of heart diseases and thrombosis.
{"title":"Evaluation of Antiplatelet Aggregation and Anticoagulant Effects of Oxalis Debilis Kunth Rhizome Extracts","authors":"Nguyen Thi Van Anh, Nguyen Ngoc Trang","doi":"10.25073/2588-1132/vnumps.4578","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4578","url":null,"abstract":"Cardiovascular disease is one of the leading causes of death globally. The discovery and use of natural products in the prevention and treatment of cardiovascular diseases have achieved great interest. Oxalis debilis is traditionally used for the treatment of various ailments. This study aimed to investigate the potential antiplatelet and anticoagulant properties of extracts derived from O. debilis rhizome. The rhizome of O. debilis was extracted with methanol and then fractionated to obtain four extracts: the total methanol extract, the n-hexane, ethyl acetate, and water fraction. These four extracts were then tested for their ability to inhibit platelet aggregation and blood coagulation in human blood samples. This report demonstrated for the first time that O. debilis had inhibitory effects on platelet aggregation induced by both adenosine diphosphate and collagen as well as blood coagulation. Moreover, the total methanol extract, the ethyl acetate, and the water fraction had strong antiplatelet aggregation effects. All tested extracts had mild anticoagulant activities. This plant could be a valuable natural source for searching for antithrombotic substances, or for the development of supplementary products for the treatment and prevention of heart diseases and thrombosis. \u0000 ","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":" 37","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140218023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-22DOI: 10.25073/2588-1132/vnumps.4547
Tran Quang Trung, Nguyen Thi Thanh Hai, Trinh Van Lau
This study aimed to assess the bioavailability of experimental extended-release nifedipine tablets of push-pull osmotic pump type composed of a semipermeable membrane-coated bilayer core tablet containing PEO N10 and PEO 303 in drug layer and push layer, respectively on dogs. A test on dogs was performed using a two-way randomized crossover design with a single oral dose, fasting condition. Plasma samples were obtained at intervals and analyzed for nifedipine by UPLC-MS/MS after liquid-liquid extraction using glibenclamide as the internal standard. The pharmacokinetic parameters were calculated and the bioavailability of nifedipine extended-release tablets was evaluated by comparing the pharmacokinetic parameters between the prepared extended-release tablets of 30 mg NIF and the reference tablets of Adalat LA 30 mg. It was found that the prepared push-pull osmotic pump tablets of 30 mg nifedipine were equivalent in bioavailability to Adalat LA reference tablets of 30 mg nifedipine in experimental dogs according to the regulations of US-FDA and Vietnamese pharmacopeia 5th edition. The main pharmacokinetic parameters of nifedipine test and reference tablets after a single oral administration were as follows: Cmax 26.95 ± 7.82 (ng.mL-1) and 27.20 ± 6.99 (ng.mL-1), Tmax 12.33 ± 3.44 hours and 11.50 ± 3.33 hours, AUC0-96 728.96 ± 328.87 (ng.h.mL-1) and 702.48 ± 404.48 (ng.h.mL-1), AUC0-∞, 741.05 ± 340.39 (ng.h.mL-1) and 710.71 ± 408.76 (ng.h.mL-1), MRT 21.80 ± 5.25 hours and 22.06 ± 5.20 hours, respectively. The 90% confidence intervals for the ratio of Cmax, AUC0-∞, and MRT values for the test and reference products, using logarithmically transformed data were 90.82% - 108.09%, 91.97% - 118.21%, 90.74% -107.62%, respectively. No statistically significant difference was found for the Tmax value.
{"title":"Bioavailability Study of Experimental Push–pull Osmotic Pump Tablet of Nifedipine in Dogs","authors":"Tran Quang Trung, Nguyen Thi Thanh Hai, Trinh Van Lau","doi":"10.25073/2588-1132/vnumps.4547","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4547","url":null,"abstract":"This study aimed to assess the bioavailability of experimental extended-release nifedipine tablets of push-pull osmotic pump type composed of a semipermeable membrane-coated bilayer core tablet containing PEO N10 and PEO 303 in drug layer and push layer, respectively on dogs. A test on dogs was performed using a two-way randomized crossover design with a single oral dose, fasting condition. Plasma samples were obtained at intervals and analyzed for nifedipine by UPLC-MS/MS after liquid-liquid extraction using glibenclamide as the internal standard. The pharmacokinetic parameters were calculated and the bioavailability of nifedipine extended-release tablets was evaluated by comparing the pharmacokinetic parameters between the prepared extended-release tablets of 30 mg NIF and the reference tablets of Adalat LA 30 mg. It was found that the prepared push-pull osmotic pump tablets of 30 mg nifedipine were equivalent in bioavailability to Adalat LA reference tablets of 30 mg nifedipine in experimental dogs according to the regulations of US-FDA and Vietnamese pharmacopeia 5th edition. The main pharmacokinetic parameters of nifedipine test and reference tablets after a single oral administration were as follows: Cmax 26.95 ± 7.82 (ng.mL-1) and 27.20 ± 6.99 (ng.mL-1), Tmax 12.33 ± 3.44 hours and 11.50 ± 3.33 hours, AUC0-96 728.96 ± 328.87 (ng.h.mL-1) and 702.48 ± 404.48 (ng.h.mL-1), AUC0-∞, 741.05 ± 340.39 (ng.h.mL-1) and 710.71 ± 408.76 (ng.h.mL-1), MRT 21.80 ± 5.25 hours and 22.06 ± 5.20 hours, respectively. The 90% confidence intervals for the ratio of Cmax, AUC0-∞, and MRT values for the test and reference products, using logarithmically transformed data were 90.82% - 108.09%, 91.97% - 118.21%, 90.74% -107.62%, respectively. No statistically significant difference was found for the Tmax value. \u0000 ","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":" 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140211919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-22DOI: 10.25073/2588-1132/vnumps.4541
Dao Huyen Quyen, Dao Thi Khanh Linh, Vu Van Nga, Le Thi Minh Phuong, Do Thi Quynh
Tacrolimus, a calcineurin inhibitor, is a first-choice drug for the anti-rejection treatment regimen after kidney transplantation. The daily adjusted Tacrolimus dose by therapeutic drug monitoring is essential for patients to achieve optimal effects and minimize complications. We conducted a retrospective analysis of 70 kidney transplant patients at Bach Mai Hospital from January 2019 to the end of June 2020 to monitor changes in the blood trough level of Tacrolimus over time and analyze some risk factors affecting the blood trough level of Tacrolimus after a kidney transplant. Total whole-blood samples were collected at 6 time points: pre-transplant, on transplant day, and the 1st, 2nd, 4th, and 8th day after surgery. During the study, we recorded 4 cases with accelerated acute rejection with the blood trough level of Tacrolimus on the first day after transplantation of 5.325 ± 1.531 ng/mL and lower than the medium level in the remaining group of patients 10.371 ± 4.550 ng/mL at the same time (p = 0.031). There was no significant difference between the two groups of patients in age, gender, BMI, chronic disease status (hypertension, hepatitis C, type 2 diabetes), pre-transplant blood urea, and serum creatinine concentrations. These characteristics were included in the linear regression models which affected the blood trough level of Tacrolimus. This showed that none of the above risk factors had a significant effect on the blood trough level of Tacrolimus on the first day after transplantation (p > 0.05).
{"title":"Studying the Blood Trough Level of Tacrolimus on Patients after Kidney Transplant at the Uronephreulogical Department, Bach Mai Hospital, Vietnam","authors":"Dao Huyen Quyen, Dao Thi Khanh Linh, Vu Van Nga, Le Thi Minh Phuong, Do Thi Quynh","doi":"10.25073/2588-1132/vnumps.4541","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4541","url":null,"abstract":"Tacrolimus, a calcineurin inhibitor, is a first-choice drug for the anti-rejection treatment regimen after kidney transplantation. The daily adjusted Tacrolimus dose by therapeutic drug monitoring is essential for patients to achieve optimal effects and minimize complications. We conducted a retrospective analysis of 70 kidney transplant patients at Bach Mai Hospital from January 2019 to the end of June 2020 to monitor changes in the blood trough level of Tacrolimus over time and analyze some risk factors affecting the blood trough level of Tacrolimus after a kidney transplant. Total whole-blood samples were collected at 6 time points: pre-transplant, on transplant day, and the 1st, 2nd, 4th, and 8th day after surgery. During the study, we recorded 4 cases with accelerated acute rejection with the blood trough level of Tacrolimus on the first day after transplantation of 5.325 ± 1.531 ng/mL and lower than the medium level in the remaining group of patients 10.371 ± 4.550 ng/mL at the same time (p = 0.031). There was no significant difference between the two groups of patients in age, gender, BMI, chronic disease status (hypertension, hepatitis C, type 2 diabetes), pre-transplant blood urea, and serum creatinine concentrations. These characteristics were included in the linear regression models which affected the blood trough level of Tacrolimus. This showed that none of the above risk factors had a significant effect on the blood trough level of Tacrolimus on the first day after transplantation (p > 0.05). \u0000 \u0000 ","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"221 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140214395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-22DOI: 10.25073/2588-1132/vnumps.4543
Nguyen Ngoc Nha Thao, Nguyen Thi Trang Dai
Published research showed that mango seeds have good anti-inflammatory and antibacterial properties. The purpose of this study is to develop a microemulsion formula containing mango seed extract for application in the treatment of inflammatory acne. Isopropyl myristate and coconut oil were selected as the fixed oil phase components. Phase diagrams for the microemulsion regions were constructed using PEG 40 hydrogenated castor oil as surfactant and PEG 400 as co-solvent. Microemulsions were prepared by titration and mixed with mango seed extract. Microemulsions and the physical and chemical stability of the microemulsion were evaluated for droplet size and PDi index using dynamic light scattering techniques. The microemulsion was gelled and evaluated for its anti-inflammatory effect by comparing it with an acne cream on the market. The selected microemulsion formula has a ratio of isopropyl myristate oil to coconut oil of 1:2, Smix/Co is PEG 40 hydrogenated castor oil to PEG 400 with a ratio of 3:1, and a high loading efficiency of 5% mango seed. The average particle size of the microemulsion reached 22.74 nm. The selected microemulsion showed good stability, with almost no change in particle size when stored at room temperature after 30 days. The microemulsion was gelled with 7% carbopol, and the permeability of polyphenols from the microemulsion gel within 6 hours was observed to be about 59.61%. The microemulsion gel inhibited the denaturation of bovine serum albumin, indicating that the microemulsion containing coconut oil and mango extract may help in treating inflammatory acne. Microemulsion gel containing mango seed kernel has been successfully studied, has anti-inflammatory activity equivalent to a modern control drug, and is promising as a natural preparation that can provide anti-inflammatory protection on acne skin. However, further clinical studies need to be conducted before use.
{"title":"Formulation of Microemulsion-based Gel Containing Mango Seed Kernel Extract for Application in Anti-inflammation","authors":"Nguyen Ngoc Nha Thao, Nguyen Thi Trang Dai","doi":"10.25073/2588-1132/vnumps.4543","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4543","url":null,"abstract":"Published research showed that mango seeds have good anti-inflammatory and antibacterial properties. The purpose of this study is to develop a microemulsion formula containing mango seed extract for application in the treatment of inflammatory acne. Isopropyl myristate and coconut oil were selected as the fixed oil phase components. Phase diagrams for the microemulsion regions were constructed using PEG 40 hydrogenated castor oil as surfactant and PEG 400 as co-solvent. Microemulsions were prepared by titration and mixed with mango seed extract. Microemulsions and the physical and chemical stability of the microemulsion were evaluated for droplet size and PDi index using dynamic light scattering techniques. The microemulsion was gelled and evaluated for its anti-inflammatory effect by comparing it with an acne cream on the market. The selected microemulsion formula has a ratio of isopropyl myristate oil to coconut oil of 1:2, Smix/Co is PEG 40 hydrogenated castor oil to PEG 400 with a ratio of 3:1, and a high loading efficiency of 5% mango seed. The average particle size of the microemulsion reached 22.74 nm. The selected microemulsion showed good stability, with almost no change in particle size when stored at room temperature after 30 days. The microemulsion was gelled with 7% carbopol, and the permeability of polyphenols from the microemulsion gel within 6 hours was observed to be about 59.61%. The microemulsion gel inhibited the denaturation of bovine serum albumin, indicating that the microemulsion containing coconut oil and mango extract may help in treating inflammatory acne. Microemulsion gel containing mango seed kernel has been successfully studied, has anti-inflammatory activity equivalent to a modern control drug, and is promising as a natural preparation that can provide anti-inflammatory protection on acne skin. However, further clinical studies need to be conducted before use. \u0000 ","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":" 33","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140215828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：